Anti-C5 antibody [EPR23940-46] - BSA and Azide free (Capture)

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

C5 also known as complement 5 is a protein with a mass of approximately 190 kDa. This protein plays a mechanical role as part of the complement system within the immune response. C5 is expressed in the bloodstream and is produced mainly by the liver. Upon activation it splits into C5a and C5b where C5a acts as a potent anaphylatoxin while C5b initiates the assembly of the membrane attack complex. Due to its important functions the production and regulation of C5 are tightly controlled within the body.

Biological function summary

The activation of this target contributes significantly to inflammatory processes and host defense. It is part of the larger complement system where it aligns with other complement proteins like C3 and forms a pathway important for immune system functioning. C5 is integral to the terminal complement complex formation which results in the lysis of target cells. The cleavage product C5a has near-instant effects as a chemotactic agent recruiting other immune cells to sites of infection.

Pathways

The protein has a fundamental position in the classical and alternative complement pathways. These pathways converge at the level of C5 where its cleavage is necessary for further downstream effects. C5 interacts extensively with C3 in these pathways highlighting their joint role in amplifying the immune response. The membrane attack complex which C5 helps initiate is a vital endpoint in these pathways promoting the destruction of pathogen cell membranes.

Associated diseases and disorders

C5 has been linked to conditions like hereditary angioedema and atypical hemolytic uremic syndrome. Dysregulation of C5 or its pathways can lead to chronic inflammation excessive tissue damage or inefficient pathogen clearance. In such conditions related proteins like C3 also show altered activity patterns. Targeting C5 with specific antibodies has emerged as a therapeutic strategy to manage these diseases aiming to mitigate the pathological activation of the complement system.